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Abstract 12 
Canine Papillomaviruses (CPVs) have been identified in various benign and malignant 13 
neoplastic skin disorders. The most frequent manifestations of CPV infections are classical 14 
warts and pigmented plaques.  Although the etiology of canine oral papillomatosis is well 15 
established, knowledge about CPVs` role in the development of pigmented plaques remains 16 
vague. Indeed, as CPV DNA may frequently be found on clinically healthy canine skin, its 17 
mere detection in lesions cannot be regarded as a sufficient indicator of causality. Whether 18 
CPVs are actually active in pigmented plaques, a requirement for any conceivable 19 
involvement, is consequently an open question. To enquire such viral activity, two distinct 20 
clinical cases of canine pigmented lesions were evaluated in greater detail. The histological 21 
findings in the two cases supported the clinical diagnosis of pigmented viral plaques. 22 
Sequencing of amplified DNA from these lesions revealed the genomes of two novel CPV 23 
types, i.e. CPV9 and CPV14, both putatively belonging to the genus Chi. Furthermore, 24 
transcription and splicing of corresponding CPV mRNA could be shown by RT-PCR in the 25 
respective lesions. Finally, viral particles were detected by electron microscopy in 26 
homogenates as well as in nuclei of keratinocytes in pigmented lesions. In conclusion, the 27 
results link clinical signs of pigmented plaques to histological changes, the presence of CPV 28 
specific DNA, viral gene transcription, and the presence of viral particles in and from the 29 
lesions. Thus, the findings outline the entire replicative cycle of CPVs in pigmented plaques, 30 
which might help understanding the relationship between these viruses and the associated 31 
disorders. 32 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Introduction 35 
Papillomaviruses are small double stranded DNA viruses with a circular genome of about 8 36 
kilo base pairs packaged into an icosahedral capsid of around 50nm (Howley and Lowy, 37 
2007). They are taxonomically grouped in the family Papillomaviridae that is expected to 38 
have a long evolutionary history due to its enormous genetic diversity. More than 200 types of 39 
papillomaviruses have already been identified in a broad variety of species, most of them in 40 
humans (Bernard et al., 2010). Papillomaviruses primarily infect keratinocytes and have been 41 
proven or proposed to play an important role in the development of benign and malignant 42 
tumors in mucous membranes and the keratinizing skin (Howley and Lowy, 2007). 43 
Papillomaviruses depend very much on the lifecycle of keratinocytes which are their 44 
primarily host cells. The papillomavirus lifecycle can be divided into three phases. In the first 45 
phase an infection is established, which requires binding, entry, uncoating, nuclear transport 46 
and an initial amplification of the viral DNA in the nucleus. In the second phase, that might 47 
be very long, the viral gene expression is very low and the episomal papillomavirus genomes, 48 
which might be just some to a few hundred per cell, are copied in synchrony with the cellular 49 
DNA. In the third or late phase, which is initiated by yet unknown differentiation associated 50 
cellular factors, structural proteins are expressed and viral particles assemble in the nucleus of 51 
the terminally differentiating keratinocytes (Howley and Lowy, 2007, Egawa et al. 2012).  52 
During the different phases of the papillomavirus lifecycle the viral gene expression differs 53 
significantly, consequently the viral Open Reading Frames (ORFs) were termed early (E) and 54 
late (L) ones. Thus the viral genome has an early and a late region, which usually have a 55 
polyadenylation site each. While the late genes L1 and L2, which code for the capsid proteins, 56 
are only expressed in the late phase of an infection, others namely E6 and E7 are rather 57 
constantly expressed at a low level. The proteins encoded by E1 and E2, which are the viral 58 
  4 
players involved in replication, seem to be primarily needed in the first and third phase. 59 
Although the number of ORFs in a papillomavirus genome is usually only seven or eight, the 60 
number of expressed proteins exceeds this significantly due to intensive and alternative 61 
splicing. One of these spliced mRNAs codes for E1^E4 that is actually a late protein involved 62 
in packaging of the viral DNA (Howley and Lowy, 2007, Egawa et al. 2012). 63 
As for their pathogenic role papillomaviruses are today well-studied pathogens of humans 64 
primarily in the context of cervix carcinomas and condylomas, which are a major health issue 65 
globally. Nevertheless there are also several benign and also malignant maladies of the 66 
keratinizing skin that are caused by or connected to papillomavirus infections, including the 67 
common warts, epidermoplasia veruciformis (EV) and carcinomas. Still, not only humans 68 
suffer from papillomavirus infections. Exophytic and endophytic warts, pigmented plaques 69 
and also in situ and invasive squamous cell carcinomas of dogs have been linked to 70 
papillomaviruses, and there is increasing evidence, that there is a causal relationship beyond 71 
oral papillomatosis. So far the genomes of nine canine papillomaviruses (CPVs) have been 72 
reported, as well as a couple of partial ones (Zaugg et al., 2005, Lange et al., 2010, Munday et 73 
al., 2011, Luff et al., 2012). All known CPVs can be allocated to three distinct papillomavirus 74 
genera, namely Lambda (CPVs 1 and 6), Tau (CPVs 2 and 7) and Chi (CPVs 3, 4, 5, 8 and 9) 75 
based on their L1 nucleotide sequences (Delius et al., 1994, Tobler et al., 2006, Yuan et al., 76 
2007, Tobler et al., 2008, Lange et al., 2009, Bernard et al., 2010, Lange et al., 2012, Yuan et 77 
al., 2012). Based on the available data it appears, that all the pigmented plaques in dogs may 78 
be caused by Chi papillomaviruses.  79 
Although there is good evidence that papillomaviruses do induce lesions in dogs, 80 
papillomavirus DNA is frequently found on clinically healthy skin of dogs and other species 81 
(Antonsson and Hansson 2002, Lange et al., 2011). If these findings amount to subclinical 82 
infections, then additional factors may be required to trigger apparent clinical papillomatosis. 83 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Such might be genetic as in human EV, induced immunosuppression as in organ recipients, 84 
acquired like in HIV patients or due to exposure to other external stimuli like UV light or 85 
chemicals (zur Hausen 2009, Heard 2011). Several reports from the past years support this 86 
hypothesis, however, the sole identification of viral DNA in lesions leaves room for debate 87 
whether or not the virus is active and thus putatively playing an active role or not (Le Net et 88 
al., 1997, Callan et al., 2005, Favrot et al., 2005, Goldschmidt et al., 2006). To determine if 89 
there is ongoing virus activity in plaque-like pigmented lesions, two cases of papillomatosis 90 
involving novel Chi papillomaviruses were analyzed in detail, including clinical assessment, 91 
histology, PCR, molecular cloning, sequence analysis, phylogenetic analysis, transcription 92 
analysis and electron microscopy. 93 
 94 
Materials and Methods 95 
Samples 96 
Two dogs were included in this study, which were both presented at the veterinary teaching 97 
hospital of the University of Zurich. The first dog was a ten year old female castrated Golden 98 
retriever presenting with several hyperpigmented, plaque-like, non-pruritic lesions on the 99 
right dorsal foreleg. Most of the lesions were pedunculated, giving the lesion a scaly 100 
appearance (Fig. 1). Six years before the dog had been diagnosed with low-grade lymphoma. 101 
After a short period of a higher dose in the beginning, the dog received 0,3mg/kg 102 
prednisolone every other day and 0,05mg/kg chlorambucil daily as therapy. 103 
The second dog was an eight-month-old intact black pug showing several pigmented plaques 104 
on the abdomen, right medial thigh, right knee and neck. The lesions were non-pruritic. The 105 
dog had previously been presented because of a subclinical extra hepatic porto-systemic shunt 106 
and a generalized juvenile demodicosis, both being diagnosed 4 month earlier. The 107 
  6 
demodicosis was cured at the time, the pigmented plaques developed; the porto-systemmic 108 
shunt was closed by cellophane ligation 3 month earlier. 109 
Initially in each of the cases one 6mm punch biopsy for histopathological examination and 110 
one cytobrush sample for microbiological assessment were taken from the lesions. The 111 
cytobrush was moistened with sterile 0.9% NaCl solution, rubbed for thirty seconds on the 112 
affected area and stored in an 1.5ml Eppendorf tube at -20°C until DNA extraction. The tissue 113 
samples were fixed in 4% buffered formalin. After embedding in paraffin, 4 µm sections were 114 
stained with haematoxylin and eosin (HE) for histopatholgical examination. 115 
Upon a second visit samples for transmission electron microscopy and negative stain as well 116 
as for RNA assessment were taken. To preserve the RNA the respective samples were placed 117 
in RNA later (Sigma-Aldrich) and stored according to the protocol. 118 
 119 
Electron microscopy 120 
The biopsies were fixed with 2.5% glutaraldehyde in 0.1M Na/K-phosphate, pH 7.4, at 4°C 121 
for 1 h, kept in 0.1M Na/K-phosphate at 4°C overnight, post-fixed with 1% osmium tetroxide 122 
in 0.1M Na/K-phosphate at 4°C for 1 h, dehydrated in a graded ethanol series starting at 70% 123 
and, after two changes in acetone, embedded in epon. 50 – 60 nm thick sections were stained 124 
with uranylacetate and lead citrate, and analyzed in a transmission electron microscope (CM 125 
12, Philips, Eindhoven, The Netherlands) equipped with a CCD camera (Ultrascan 1000, 126 
Gatan, Pleasanton, CA, USA) at an acceleration voltage of 100 kV. 127 
For negative staining, the biopsies were cut with a razor blade into small cubes, and after 128 
three cycles of freezing and thawing, centrifuged in an eppendorf centrifuge at maximal 129 
speed. From the supernatant, virus particles were adsorbed for 10 min to carbon coated 130 
parlodion films mounted on 300 mesh/inch copper grids (EMS; Fort Washington, PA, USA), 131 
  7 
washed once with distilled water, and stained with 2% phosphotungstic acid (Sigma Aldrich, 132 
Gilingham- Dorset, UK), pH 7.0, at room temperature for 1 min. Specimens were analyzed in 133 
a transmission electron microscope CM 12, equipped with a CCD camera Ultrascan 1000 at 134 
an acceleration voltage of 100 kV. 135 
 136 
Identification, Amplification and cloning of genomes 137 
Total DNA of 25 mg tissue samples was isolated using a DNeasy extraction kit (Qiagen) 138 
according to the manufacturer's recommendations. For initial identification of host and PV 139 
DNA in the samples GAPDH f/r, CP4/CP5 and canPV/FAP64 PCR assays were applied 140 
(Iftner et al., 2003, Lange et al., 2011). PCR products were determined (Microsynth) by cycle 141 
sequencing using an ABI 377 sequencer (Applied Biosystems) and compared to the NCBI 142 
database (BLAST X). For cloning purposes one microliter of the DNA extract was used for 143 
rolling circle amplification (RCA) (Rector et al., 2004), using a TempliPhi Amplification kit 144 
(General Electrics Biosciences). Slight modifications were applied to the protocol supplied by 145 
the manufacturer (Lange et al., 2009). Amplified DNA from case one (CPV14) was cloned 146 
into the BamHI, EcoRI or XbaI site of pBluescript II KS+ (Stratagene), while the DNA 147 
amplified from case two was cloned into the SalI site (CPV9) using standard procedures. The 148 
cloned DNA sequences of the PV candidates were determined (Microsynth) and primary 149 
sequences were assembled using Contigexpress software (Vector NTI Informax, Invitrogen).  150 
The nucleotide sequence data of CPV14 were deposited in GenBank under accession no. 151 
JQ701802. 152 
 153 
Sequence analysis 154 
The coding sequences for the E6, E7, E1, E2, L2 and L1 proteins from the CPVs, feline 155 
  8 
papillomaviruses (FdPVs) and bovine papillomavirus 1 (BPV1) were translated and aligned 156 
by using MAFFT (Katoh and Toh, 2008) before being back-translated to DNA sequences. 157 
The six sets of aligned nucleotide sequences representing the six sets of protein sequences 158 
were shortened by using GBLOCK (version 0.91b; http://molevol.cmima.csic.es/castresana/) 159 
(Castresana et al., 2000) and combined to a single multiple sequence alignment (MSA) by 160 
concatenating the sequences from each virus. The optimal model of DNA evolution was 161 
evaluated for best fit of the data set using MODELTEST (version 1.4.4; 162 
http://darwin.uvigo.es/; default settings) (Posada 1998). Bayesian phylogeny was inferred 163 
using MRBAYES (version 3.2; http://mrbayes.csit.fsu.edu/; Markov Chain Monte Carlo with 164 
GTR substitution matrix, variable gamma rates, invariant sites, two runs four chains of 165 
10,000,000 generations), and displayed with FIGTREE (1.3.0 http://tree.bio.ed.ac.uk/) 166 
(Drummond et al., 2007). Pairwise sequence alignments were performed using NEEDLE 167 
(EMBOSS, nucleotide matrix: DNAFULL, amino acid matrix: BLOSSUM62). Splice sites 168 
were predicted by the on-line version of NETGENE2 169 
(http://www.cbs.dtu.dk/services/NetGene2/) (Brunak et al., 1991). 170 
 171 
Detection of virus specific mRNA 172 
Total RNA of 25 mg tissue samples was isolated using a NucleoSpin RNA II RNA extraction 173 
kit (Machery Nagel) according to the manufacturer's recommendations. To get rid of putative 174 
remnant DNA the RNA was afterwards again digested with DNase A (Roche), 1µl DNase 175 
was added to 50 µl sample and incubated for 15 min at 37°C and afterwards 10 minutes at 176 
75°C. A Reverse Transcription System reverse transcription kit (Promega) was used 177 
according to the protocol to produce cDNA with random primers. To control the success of 178 
the DNA digestion, one sample with and one sample without reverse transcriptase (RT) each 179 
was processed. 180 
  9 
To test for RNA transcription, primer combinations amplifying fragments of the main 181 
transcripts, E6, E7, E1, E2, E1^E4, L2 and L1 were constructed (supplement 2). Except for 182 
E4 all primers were designed to amplify regions were no splicing was expected. The primers 183 
for E1^E4 PCR however were designed to identify donor and acceptor splice sites of the 184 
E1ˆE4 mRNA. PCR was performed on cDNA with and without RT, sterile water and DNA 185 
extract of lesional tissue. 186 
To determine the splice sites the E4 PCR product from the cDNA was extracted from the gel 187 
using a QIAEX II kit (QIAGEN) and sequenced (Microsynth). The sequence of the putative 188 
E4 of CPV14 was included in the file JQ701802. The putative E4 sequence information of 189 
CPV9 was deposited separate in GenBank under accession no. JQ701801. 190 
 191 
Results 192 
Clinical development 193 
The course of the papillomavirus infections after presentation varied significantly. The lesions 194 
in the Golden retriever resolved entirely within few weeks despite of continued corticosteroid 195 
treatment. In the pug on the contrary more lesions developed over the following months, but 196 
no approach of treatment was attempted.   197 
 198 
Histology 199 
In case of the included pug the histological examination revealed papillated hyperplasia and 200 
hyperpigmentation of the epidermis with large clumped keratohyalin granules. A rete ridges 201 
formation was abundant and single scattered clear cells reminiscent of koilocytes in the 202 
stratum granulosum (Fig. 1C). A diagnosis of canine viral pigmented plaques was made. 203 
  10 
The histological sections from the Golden retriever showed papillated hyperplasia and 204 
hyperpigmentation of the epidermis with large clumped keratohyalin granules. They were also 205 
found to contain disseminated apoptotic cells and some scattered clear cells reminiscent of 206 
koilocytes in the stratum granulosum (Fig. 1D). A papilloma was diagnosed. 207 
 208 
DNA  209 
In the attempt to determine whether the samples contain papillomavirus genomes, DNA was 210 
successfully amplified from the samples of the two cases by PCR. A comparison of the 211 
sequenced PCR products with the NCBI database revealed the sequence of a novel canine 212 
papillomavirus (CPV14) in the samples taken from the Golden retriever. The sequence 213 
obtained from the samples taken from the pug was found to be identical with the sequence of 214 
a very recently discovered papillomavirus (CPV9). The sequencing of cloned RCA product of 215 
CPV14 revealed a papillomavirus genome of 7784 nucleotides. Its entity was verified by 216 
direct sequencing of the RCA product. 217 
In case of both CPVs the characteristic PV open reading frames (ORFs) E1, E2, E4, E6, E7, 218 
L1 and L2 and two non-coding regions (NCR) were identified in the genome. Comparison 219 
with the other PVs on the nucleotide level using pairwise alignments (Needle, EMBOSS, 220 
http://emboss.ch.embnet.org/wEMBOSS/) identified CPV3 as the closest relative of CPV9 221 
(72% identities) and CPV8 as the closest known to CPV14 (74% identities) based on the L1 222 
ORF (Table 1). CPV9 has a GC content of 51%, CPV14 of 53%. 223 
Characteristic papillomavirus motifs were identified on the genomic sequences. Nine putative 224 
E2 binding sites (ACC-N6-GGT) could be located on the CPV9 sequence, six in the NCR, one 225 
within the E2/E4 ORF, one in the L1 and one in the L2 ORF. Flanked by E2 binding sites 226 
dyad symmetry repeats (TTGTTGTTAACAACAA) in a modified form were found 101nt 227 
  11 
upstream of the E6 ORF. Poly A signals (AATAAA) were identified at the ends of the E1 and 228 
L1 ORFs as well as at the start of the L2 ORF, also one putative SP1 binding site (GGCGGG) 229 
in the L1 ORF and 11 putative NF1 binding sites (GCCAA). The E6 amino acid sequence 230 
contains two metal binding motifs (CX2CX28-30CX2C) starting at amino acids 25 and 98, the 231 
E7 one starting at amino acid 54. The amino acid sequence of E7 also contains a putative 232 
pRB-binding motif (LXCXE). A modified ATP helicase-binding motif (GPPDTSKS) is 233 
present on the predicted E1 amino acid sequence. The CPV14 genomic sequence contains 234 
eleven putative E2 binding sites, five of them in NCR, one within the E2/E4 ORF, one in the 235 
L1 and two in the L2 ORF. Located in the NCR, 98nt upstream of the E6 ORF flanked by E2 236 
binding sites dyad symmetry repeats were identified. Poly A signals were identified within the 237 
E1 and at the ends L1 ORF. One putative AP1 binding site in the E2/E4 ORF and 12 putative 238 
NF1 binding sites were also found. Metal binding motifs were identified within the E6 amino 239 
acid sequence starting at amino acids 25 and 97 as well as in the E7 amino acid sequence 240 
starting at amino acid 54. A putative pRB-binding motif is also present in the encoded E7 241 
amino acid sequence. An ATP helicase-binding motif is present on the predicted E1 amino 242 
acid sequence. 243 
 244 
Phylogeny 245 
To allocate the two viral genomes in a phylogenetic context, they were compared to the other 246 
canine and feline papillomaviruses and a bovine papillomavirus 1 sequence. In a phylogenetic 247 
tree based on the E6, E7, E1, E2, L1 and L2 regions both CPVs appear in the branch of the 248 
Chi papillomaviruses (Fig. 2). While CPV9 clusters together with CPVs 3, 4, 5 and 11, 249 
CPV14 clusters together with CPVs 8 and 10. CPVs 9 and 14 share more than 60% of 250 
identities with the described Chi papillomaviruses CPV3, 4, 5 and 8 as well as with CPVs 10 251 
and 11. When compared on the amino acid level CPV9 shows between 78.1 and 86.8% 252 
  12 
similarity with CPVs 3, 4, 5 and 11 in the E6 sequence and with the same viruses between 253 
89.5 and 96% similarity in the E7 sequence. CPV14 shows between 74.8 and 80.6% similarity 254 
with CPVs 10 and 8 in the E6 sequence and 88.5 and 91.4% similarity in the E7 sequence 255 
(supplement 1). 256 
 257 
RNA & Splicing 258 
To determine whether the viral genes were transcribed in the lesional tissue, total RNA was 259 
extracted from fresh samples, reverse transcribed into cDNA and analyzed by PCR. Different 260 
PCRs with specific primer sets were applied to amplify cDNA of the host GAPDH mRNA, as 261 
well as of the viral mRNAs of L2, L1, E6, E7, E1, E2 and E1^E4 of CPV9 or CPV14 262 
(supplement 2). The RT-PCR revealed amplimers of expected sizes. However, no product 263 
was produced if the reverse transcriptase was omitted in the cDNA reaction (Fig. 3). 264 
Using the E1^E4 transcript specific primers, no PCR product of the expected size (3030 and 265 
3159 bp, respectively; see supplement 2) was produced from the DNA extract of the lesions. 266 
A side product of unknown origin was amplified with the CPV9 E1^E4 specific primer of 267 
about 150 bp was visible in the DNA- and the RT+-sample. The sequencing of the E1^E4 RT-268 
PCR product from the RNA samples revealed a joined sequence of the first 22 nucleotides of 269 
the E1 ORF at genome position 992 and the predicted E4 ORF from position 3382 in case of 270 
CPV9 and the first 22 nucleotides of the E1 ORF at genome position 851 and the predicted E4 271 
ORF from position 3259 in case of CPV14. These sites are in agreement with the splice 272 
donors (0.66 and 0.92 confidence for CPV9 and CPV14, respectively) and the splice 273 
acceptors (0.14 and 0.19 confidence for CPV9 and CPV14, respectively) predicted by 274 
NetGene2 (http://www.cbs.dtu.dk/services/NetGene2/).  275 
 276 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Electron Microscopy 277 
Examination of the affected epidermis by transmission electron microscopy revealed 278 
numerous, uniform round particles in nuclei of keratinocytes in the basal and granular layer of 279 
both dogs (Fig. 4 A-B). Extracts obtained after freezing and thawing contained particles of 280 
~50 nm in diameter showing the characteristic morphology of papillomavirus after negative 281 
staining with Na-phosphotungstic acid (Fig. 4 C-D). 282 
 283 
Discussion 284 
Pigmented plaques and putatively associated skin alterations are infrequently seen in dogs of 285 
various ages and have been proposed to be papillomavirus induced (Nagata et al., 1995, 286 
Narama et al., 2005, Tobler et al., 2006, Tobler et al., 2008, Lange et al., 2009, Munday et al., 287 
2011, Lange et al., Luff et al., 2012, 2012, Yuan et al., 2012). The question whether viruses 288 
are present and may be causing the observed lesions has been addressed in various ways that 289 
can be subsumed under two categories of approaches. On the one hand characteristic changes 290 
indicative of papillomavirus infections have been described and even viral particles have been 291 
found in pigmented plaques using a pathological approach (Nagata et al., 1995, Narama et al., 292 
2005). On the other hand DNA sequences of various Chi-papillomavirus types or putative 293 
types have been retrieved from pigmented plaques using rather a molecular biological 294 
approach (Lange et al., 2009, Yuan et al., 2012). Both approaches however have their 295 
strengths and weaknesses. While the visualization of macroscopic and microscopic changes 296 
and even viral particles clearly proves a pathology and virus production it fails to determine 297 
the pathogen. The identification and determination of viral DNA allows a detailed analysis of 298 
the genetics of a putative pathogen, makes some predictions about its biology possible and is 299 
very helpful to address the prevalence, but still does not tell much about the activity or role of 300 
  14 
it in the lesion. Especially a prevalence of virus DNA in nonlesional skin in many species has 301 
to be kept in mind. 302 
The two cases analyzed here resemble typical lesions associated with Chi papillomaviruses, 303 
clinically as well as from the histopathological point of view. The flat pigmented warts as 304 
seen in case two appear to be identical with the lesions associated with CPVs 4 and 8 (Tobler 305 
et al., 2008, Lange et al., 2012). Similarly the pigmented scale like lesions of case one are 306 
indistinguishable from those found in the cases associated with CPVs 3 and 5 although no 307 
pigmented plaques were apparent in case one while they were in dogs infected with CPVs 3 308 
or 5 (Tobler et al., 2006, Lange et al., 2009). The clinical diagnosis of papillomatosis was 309 
confirmed on the one hand by some characteristic histopathological alterations and the PCR 310 
based discovery of papillomavirus DNA in the lesional skin. The history of both cases also 311 
involved additional factors that are known amplificators of papillomavirus infections as they 312 
interfere with the immune system. In case of the Golden retriever this is the long time 313 
application of the immunosuppressant cortisone. In case of the pug it is the extra hepatic 314 
porto-systemic shunt, although the mechanisms by which such a defect influences the 315 
immune system are only partly understood (Koblik and Hornof, 1995). If, and if so how these 316 
putative amplificators contributed to the clinical lesions remains open. The development of 317 
the two cases suggests, that the low dose cortisone may have only partly been promoting the 318 
onset of the clinical papillomatosis as it spontaneously resolved. The shunt-induced 319 
immunosuppression thus seems to have had a longer lasting effect. However other factors 320 
including the virus itself may have been responsible for the development of the lesions. 321 
To determine if the virus is actually going to a full lifecycle in the lesions or whether it’s 322 
DNA is rather there in a silent or latent state viral gene expression was evaluated. In this 323 
context the expression of the seven viral transcripts E1, E2, E4, E6, E7, L1 and L2 indicates, 324 
that infected cells of different stages are present, as the expression of certain mRNAs is 325 
  15 
regulated according to the stage in the lifecycle of the virus and its host cell. The terminal 326 
stage of a papillomavirus lifecycle is the assembly and packaging of viral particles in its 327 
nucleus before the cell dies (Howley and Lowy, 2007). The assembled particles in the nuclei 328 
could be shown by transmission electron microscopy and viral particles could also be visualized 329 
using negative stain techniques (Fig. 4). This strongly indicates, that the entire virus life cycle 330 
of CPV9 and CPV14, respectively, must have been completed in the respective lesions. 331 
Splicing is known to be an important posttranscriptional process for papillomavirus gene 332 
expression and is likely to occur in all papillomaviruses. Although putative donor and 333 
acceptor sites can be predicted to a certain extent, the actual splicing products have to be 334 
confirmed experimentally. The presented experiments determined splice donor and acceptor 335 
sites of the E4 mRNAs of CPV9 and CPV14. 336 
The Phylogenetic analysis of the CPV sequences indicates at least two mayor branches 337 
containing three or more species within the genus Chi genus of papillomaviruses (Fig. 2). One 338 
branch contains the CPVs 3, 5, 9 and 11 that cluster well together and which would fulfill the 339 
criteria of one taxonomic species (>70% identities). CPV4 Appears to be in that branch as 340 
well, but it would represent an own species. However, in case of the second branch, which 341 
includes CPVs 8, 10 and 14 applying the species definition is not that easy. When looking at 342 
CPVs 8 and 10 independently, they would represent two different species (<70% identities), 343 
whereas CPV14 seems to be in between fulfilling the criteria for both (table 1). Such 344 
difficulties with the current definitions arise occasionally as more and more papillomavirus 345 
sequences become available and may make some revisions necessary in the future.  346 
Interestingly the degree of similarities in the encoded amino acid sequences of E6 and E7 347 
resemble very well the phylogenetic tree. As proteins encoded by the E6 and the E7 gene are 348 
supposedly the products that have the most influence on papillomavirus pathologies this 349 
indicates some biological relevance (supplement 1). A huge amount of clinical data would 350 
  16 
however be needed to determine whether the clinical outcome of infections with different Chi 351 
papillomaviruses may differ due to the virus type involved or due to host or other factors.  352 
Proving causality between papillomavirus infections and associated lesions has always been a 353 
challenge. Yet, demonstration of not only presence but also active gene expression and 354 
completion of the viral life cycle of CPV9 and CPV14, respectively, in those lesions brings us 355 
at least one step closer to the goal. Although that does not prove causality, these findings do 356 
support such a hypothesis. 357 
In summary two novel papillomaviruses have been found, sequenced, analyzed in a 358 
phylogenetic context and shown to exist and express their genes in lesions frequently 359 
described as papillomavirus-associated.  360 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Figure captions: 456 
Figure 1: Pigmented plaques on the abdomen of a pug from a macroscopic (A) and 457 
microscopic perspective (HE, 10x objective). Histology reveals hyperplasia, 458 
hyperpigmentation and rete ridges formation (C). Golden retriever presenting with pigmented 459 
plaque and scale like lesions on a foreleg (B). Under the microscope (HE, 10x objective) 460 
hypergranulosis, hyperkeratosis and apoptotic cells are visible (D). 461 
 462 
Figure 2: Bayesian phylogenetic tree based on the alignment of E6, E7, E1, E2, L1 and L2. 463 
The PV-types (with GenBank accession numbers) included are: bovine - BPV1 (X02346); 464 
canine - CPV1 (L22695), CPV2 (AY722648), CPV3 (NC_008297), CPV4 (NC_010226), 465 
CPV5 (FJ492743), CPV6 (FJ592744), CPV7 (FJ492743), CPV8 (HM796884), CPV9 466 
(NC_016074), CPV10 (NC_016075), CPV11 (NC_016076) and CPV14; feline - FdPV1 467 
(NC_004765) and FdPV2 (EU796884). Numbers at internal nodes represent the posterior 468 
probability support values. 469 
 470 
Figure 3: Agarose gel electrophoresis of the PCR results obtained from the Golden retriever 471 
(A) and the pug (B). PCR assays for seven characteristic papillomavirus genes L2, L1, E6, 472 
E7, E1, E2 and E4 of CPV14 (A) and CPV9 (B) and for the host gene GAPDH. Analyzed 473 
samples were total RNA extract with reverse transcription (RT+), total RNA extract without 474 
reverse transcription (RT-), total DNA extract (DNA) and elution buffer AE (Buffer). One 475 
hundred base pair ladder with fragment sizes from 100bp to 1500bp (in 100bp steps) and a 476 
2072bp band, indicates product sizes (Marker). 477 
 478 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Figure 4: Transmission electron micrographs of the lesional epidermis of the pug (A) and the 479 
Golden retriever (B) showing the nuclei of keratinocytes full with uniform round electrodense 480 
particles; bar 0.5µm. Extracts of lesional tissue from the pug (C) and the Golden retriever (D) 481 
showing round electrodense particles in negative stain electromicroscopy; bar 50nm. 482 
Table 1 
Comparison of the L1 ORFs at the nucleotide level, values in percentage identities 
 
 CPV1 CPV2 CPV3 CPV4 CPV5 CPV6 CPV7 CPV8 CPV9 CPV10 CPV11 CPV14 
CPV1  57 54 56 57 69 58 60 58 56 55 58 
CPV2 57  55 53 56 56 70 57 55 57 54 55 
CPV3 54 55  64 73 53 54 62 72 62 73 61 
CPV4 56 53 64  66 56 55 63 67 62 64 63 
CPV5 57 56 73 66  56 55 62 71 63 73 61 
CPV6 69 56 53 56 56  56 57 54 56 55 55 
CPV7 58 70 54 55 55 56  57 55 55 55 56 
CPV8 60 57 62 63 62 57 57  64 71 62 74 
CPV9 58 55 72 67 71 54 55 64  64 71 61 
CPV10 56 57 62 62 63 56 55 71 64  63 68 
CPV11 55 54 73 64 73 55 55 62 71 63  61 
CPV14 58 55 61 63 61 55 56 74 61 68 61  
 




Identity [E1.tfa]:
bpv1 cpv01 cpv02 cpv03 cpv04 cpv05
bpv1 100 38.4 34 38.4 39.3 39.4
cpv01 38.4 100 44.1 41.4 42 42.3
cpv02 34 44.1 100 42.6 41.6 42.1
cpv03 38.4 41.4 42.6 100 71.3 78.1
cpv04 39.3 42 41.6 71.3 100 75.4
cpv05 39.4 42.3 42.1 78.1 75.4 100
cpv06 41.6 63.4 44.9 43 44.5 44
cpv07 33 43 70.1 40.2 39.3 40.3
cpv08 37.7 43.4 40.6 56 58.6 59.6
cpv09 39 41.1 42.6 74.3 73 83
cpv10 37.5 43.9 41.7 57.5 58.2 59.8
cpv11 39.4 41.2 41.7 79 75.4 87.3
cpv14 39.2 44.8 40.4 56.5 58.1 57.3
fdpv1 40.5 60.9 42.9 43 46 43.9
fdpv2 38.4 48.7 43.6 44.2 47.6 46.1
Similarity [E1.tfa]:
bpv1 cpv01 cpv02 cpv03 cpv04 cpv05
bpv1 100 61.6 59.4 61.7 61 63
cpv01 61.6 100 68.8 67.2 66 68.6
cpv02 59.4 68.8 100 66.1 65.9 66.3
cpv03 61.7 67.2 66.1 100 86.3 90.3
cpv04 61 66 65.9 86.3 100 89.5
cpv05 63 68.6 66.3 90.3 89.5 100
cpv06 64 81.4 70.4 64.5 67.2 67.7
cpv07 61 66.8 85.2 65 63.2 65.8
cpv08 62.7 70.7 65.3 77.6 80 81
cpv09 61.2 66.4 64.7 87 87.6 92.9
cpv10 62.8 71.7 66.3 77.7 79.1 80.1
cpv11 62.7 68.7 66.4 90.5 90.5 96.5
cpv14 61.7 69.1 65.9 76.5 79.4 79.5
fdpv1 63.6 80.7 67.5 66.5 68.8 68.5
fdpv2 61 71 69.5 66.9 69.9 69.8
cpv06 cpv07 cpv08 cpv09 cpv10 cpv11 cpv14
41.6 33 37.7 39 37.5 39.4 39.2
63.4 43 43.4 41.1 43.9 41.2 44.8
44.9 70.1 40.6 42.6 41.7 41.7 40.4
43 40.2 56 74.3 57.5 79 56.5
44.5 39.3 58.6 73 58.2 75.4 58.1
44 40.3 59.6 83 59.8 87.3 57.3
100 41.7 45.2 46 45.8 44.8 45.9
41.7 100 40.9 39.8 41.4 39.7 41
45.2 40.9 100 58 72.4 58.2 79.4
46 39.8 58 100 59.1 79.8 57.5
45.8 41.4 72.4 59.1 100 59.3 71.3
44.8 39.7 58.2 79.8 59.3 100 59.1
45.9 41 79.4 57.5 71.3 59.1 100
71.3 39.6 45 42.8 44.3 43.7 47.2
51.7 43.2 48.2 45.2 46.2 45 49.6
cpv06 cpv07 cpv08 cpv09 cpv10 cpv11 cpv14
64 61 62.7 61.2 62.8 62.7 61.7
81.4 66.8 70.7 66.4 71.7 68.7 69.1
70.4 85.2 65.3 64.7 66.3 66.4 65.9
64.5 65 77.6 87 77.7 90.5 76.5
67.2 63.2 80 87.6 79.1 90.5 79.4
67.7 65.8 81 92.9 80.1 96.5 79.5
100 67.1 68.6 67.2 69 67.9 67.3
67.1 100 67.4 64.7 67.8 64.6 66.6
68.6 67.4 100 78.5 89.8 80.8 93.1
67.2 64.7 78.5 100 79.5 91.4 77.7
69 67.8 89.8 79.5 100 80.5 89
67.9 64.6 80.8 91.4 80.5 100 79
67.3 66.6 93.1 77.7 89 79 100
86.9 65.4 67.8 66.8 68.3 66.9 67.7
74 68.6 71.7 68.6 71.2 70.1 71.9
fdpv1 fdpv2
40.5 38.4
60.9 48.7
42.9 43.6
43 44.2
46 47.6
43.9 46.1
71.3 51.7
39.6 43.2
45 48.2
42.8 45.2
44.3 46.2
43.7 45
47.2 49.6
100 50.8
50.8 100
fdpv1 fdpv2
63.6 61
80.7 71
67.5 69.5
66.5 66.9
68.8 69.9
68.5 69.8
86.9 74
65.4 68.6
67.8 71.7
66.8 68.6
68.3 71.2
66.9 70.1
67.7 71.9
100 69.7
69.7 100
Identity [E2.tfa]:
bpv1 cpv01 cpv02 cpv03 cpv04 cpv05
bpv1 100 30.4 25.5 28.7 29.5 27.1
cpv01 30.4 100 27.1 29.9 31.8 32.7
cpv02 25.5 27.1 100 29.8 29.1 28.6
cpv03 28.7 29.9 29.8 100 49.9 59.3
cpv04 29.5 31.8 29.1 49.9 100 47.7
cpv05 27.1 32.7 28.6 59.3 47.7 100
cpv06 30.6 51.6 29.3 32.4 33 31.6
cpv07 27.3 28.6 50.8 28.9 27.4 30.2
cpv08 25.8 30.7 28.4 41.5 40.2 41
cpv09 28.6 30.8 28 55.6 46.9 57.7
cpv10 27.2 32.5 26.3 39.7 40.8 39.4
cpv11 29 30.1 29 56.2 49.2 66.3
cpv14 25.5 30.1 27.8 38.2 36.7 41
fdpv1 31.4 51.3 29.9 31.6 32.7 32.6
fdpv2 28.4 31.1 34.7 31.5 31.4 33.4
Similarity [E2.tfa]:
bpv1 cpv01 cpv02 cpv03 cpv04 cpv05
bpv1 100 53.7 45.1 47.5 47.9 46.7
cpv01 53.7 100 43.7 49.9 52.1 53.2
cpv02 45.1 43.7 100 53.4 52 52.6
cpv03 47.5 49.9 53.4 100 69.9 76.2
cpv04 47.9 52.1 52 69.9 100 68
cpv05 46.7 53.2 52.6 76.2 68 100
cpv06 51.7 73.2 47.2 52 53.4 52
cpv07 47.2 47.3 70.4 47.5 48.7 51
cpv08 43.2 47.6 52.7 64.5 60.3 62.2
cpv09 49.6 54.1 49.4 76.2 69.4 78.1
cpv10 44.9 48.5 48.2 60.3 58 62.4
cpv11 50.3 53 53.9 77.7 68 82.9
cpv14 43.8 47.8 49.2 59.9 58.4 62
fdpv1 51.9 73.2 45.6 49.5 52.4 52.5
fdpv2 46.9 47.5 55 48.1 47.6 52.1
cpv06 cpv07 cpv08 cpv09 cpv10 cpv11 cpv14
30.6 27.3 25.8 28.6 27.2 29 25.5
51.6 28.6 30.7 30.8 32.5 30.1 30.1
29.3 50.8 28.4 28 26.3 29 27.8
32.4 28.9 41.5 55.6 39.7 56.2 38.2
33 27.4 40.2 46.9 40.8 49.2 36.7
31.6 30.2 41 57.7 39.4 66.3 41
100 29.7 30.3 33.7 30.8 30.7 29.7
29.7 100 30.8 26.6 30.7 28.8 29.2
30.3 30.8 100 36.7 53.7 39.3 64.4
33.7 26.6 36.7 100 37.7 54.8 37.3
30.8 30.7 53.7 37.7 100 41.1 54.9
30.7 28.8 39.3 54.8 41.1 100 37.3
29.7 29.2 64.4 37.3 54.9 37.3 100
58.2 29.9 29.9 31.7 30.5 32.9 29.5
31.5 33 33.6 31.3 32.5 33.4 33.8
cpv06 cpv07 cpv08 cpv09 cpv10 cpv11 cpv14
51.7 47.2 43.2 49.6 44.9 50.3 43.8
73.2 47.3 47.6 54.1 48.5 53 47.8
47.2 70.4 52.7 49.4 48.2 53.9 49.2
52 47.5 64.5 76.2 60.3 77.7 59.9
53.4 48.7 60.3 69.4 58 68 58.4
52 51 62.2 78.1 62.4 82.9 62
100 50.1 49.9 53.3 49.2 52.7 50.3
50.1 100 52.9 49.6 53.4 47 49.6
49.9 52.9 100 58.6 76.6 61.2 81.1
53.3 49.6 58.6 100 59.1 76.4 59.2
49.2 53.4 76.6 59.1 100 61.7 74.4
52.7 47 61.2 76.4 61.7 100 56.7
50.3 49.6 81.1 59.2 74.4 56.7 100
77.8 46.5 48.4 51.9 46.4 51.2 47.5
49.3 54.7 54.7 50.3 50.6 52.3 52.2
fdpv1 fdpv2
31.4 28.4
51.3 31.1
29.9 34.7
31.6 31.5
32.7 31.4
32.6 33.4
58.2 31.5
29.9 33
29.9 33.6
31.7 31.3
30.5 32.5
32.9 33.4
29.5 33.8
100 31.3
31.3 100
fdpv1 fdpv2
51.9 46.9
73.2 47.5
45.6 55
49.5 48.1
52.4 47.6
52.5 52.1
77.8 49.3
46.5 54.7
48.4 54.7
51.9 50.3
46.5 50.6
51.2 52.3
47.5 52.2
100 47.5
47.5 100
Identity [E6.tfa]:
bpv1 cpv01 cpv02 cpv03 cpv04 cpv05
bpv1 100 21.5 24 16.6 13.9 22
cpv01 21.5 100 29.4 27.5 26.1 24.5
cpv02 24 29.4 100 27.8 29 29.3
cpv03 16.6 27.5 27.8 100 59.6 65.1
cpv04 13.9 26.1 29 59.6 100 53.9
cpv05 22 24.5 29.3 65.1 53.9 100
cpv06 23.1 37.7 28.9 22.6 30.3 26.8
cpv07 20 28.3 46.8 24.4 25.3 23.5
cpv08 21.4 31.1 26.2 33.3 35.6 33.1
cpv09 21.4 24.6 28 73.5 58.9 64.5
cpv10 14.1 29.6 28.4 35.5 36 36.4
cpv11 18.7 24.1 28 67.3 52.8 66.2
cpv14 20 30.1 28.8 36.6 42.4 38.2
fdpv1 21 37.4 30.1 29.4 31.6 26.8
fdpv2 22.5 25.2 24.8 29.7 30.6 34.2
Similarity [E6.tfa]:
bpv1 cpv01 cpv02 cpv03 cpv04 cpv05
bpv1 100 41.9 34.3 33.7 25 36.2
cpv01 41.9 100 41.2 48.5 44.1 47.9
cpv02 34.3 41.2 100 50.6 45.1 47.8
cpv03 33.7 48.5 50.6 100 79.5 83.6
cpv04 25 44.1 45.1 79.5 100 76.3
cpv05 36.2 47.9 47.8 83.6 76.3 100
cpv06 37 62.3 52.3 43.5 51.6 43.9
cpv07 34.1 47.2 66.9 38.1 46.2 42.6
cpv08 39.9 51.4 40.9 58.5 58.3 56.4
cpv09 33.2 50.3 47.8 86.8 78.1 85.5
cpv10 30.2 52.6 40.2 50.6 50 55.2
cpv11 33.2 47.1 43.5 78.6 70.4 80.6
cpv14 31.2 50 43.8 60.1 64.2 61.2
fdpv1 34.7 59.9 48.6 47.2 51.6 47.1
fdpv2 36 46 41 52.9 51.9 53.9
cpv06 cpv07 cpv08 cpv09 cpv10 cpv11 cpv14
23.1 20 21.4 21.4 14.1 18.7 20
37.7 28.3 31.1 24.6 29.6 24.1 30.1
28.9 46.8 26.2 28 28.4 28 28.8
22.6 24.4 33.3 73.5 35.5 67.3 36.6
30.3 25.3 35.6 58.9 36 52.8 42.4
26.8 23.5 33.1 64.5 36.4 66.2 38.2
100 32.2 28.4 24.6 27.1 22.3 30.1
32.2 100 25.9 24.2 27 25.4 25.7
28.4 25.9 100 32.5 59.2 31.2 68.1
24.6 24.2 32.5 100 36 66 35.1
27.1 27 59.2 36 100 33.7 60.5
22.3 25.4 31.2 66 33.7 100 37.7
30.1 25.7 68.1 35.1 60.5 37.7 100
52.2 33.3 31.5 30.8 31.2 27.3 30.7
32 25.3 31.2 31.6 35.1 32.7 34.8
cpv06 cpv07 cpv08 cpv09 cpv10 cpv11 cpv14
37 34.1 39.9 33.2 30.2 33.2 31.2
62.3 47.2 51.4 50.3 52.6 47.1 50
52.3 66.9 40.9 47.8 40.2 43.5 43.8
43.5 38.1 58.5 86.8 50.6 78.6 60.1
51.6 46.2 58.3 78.1 50 70.4 64.2
43.9 42.6 56.4 85.5 55.2 80.6 61.2
100 56.2 51.6 41.9 49 38 49.3
56.2 100 43.7 40.6 46.6 41.4 47.4
51.6 43.7 100 53 78.2 50.6 80.6
41.9 40.6 53 100 51.8 84.3 62.3
49 46.6 78.2 51.8 100 48.8 74.8
38 41.4 50.6 84.3 48.8 100 59.7
49.3 47.4 80.6 62.3 74.8 59.7 100
75.4 55.1 51 47.8 47.4 42.2 52.1
53.6 42 48.1 53.9 49.7 52.1 53.6
fdpv1 fdpv2
21 22.5
37.4 25.2
30.1 24.8
29.4 29.7
31.6 30.6
26.8 34.2
52.2 32
33.3 25.3
31.5 31.2
30.8 31.6
31.2 35.1
27.3 32.7
30.7 34.8
100 32.7
32.7 100
fdpv1 fdpv2
34.7 36
59.9 46
48.6 41
47.2 52.9
51.6 51.9
47.1 53.9
75.4 53.6
55.1 42
51 48.1
47.8 53.9
47.4 49.7
42.2 52.1
52.1 53.6
100 52.4
52.4 100
Identity [E7.tfa]:
bpv1 cpv01 cpv02 cpv03 cpv04 cpv05
bpv1 100 17.2 17.6 12.5 15.4 18.9
cpv01 17.2 100 31.1 41 44.4 44
cpv02 17.6 31.1 100 28.4 25.5 27.9
cpv03 12.5 41 28.4 100 78.1 79
cpv04 15.4 44.4 25.5 78.1 100 80
cpv05 18.9 44 27.9 79 80 100
cpv06 20.1 57.6 36.5 32.1 37 39.6
cpv07 16.7 32.4 69.4 25 25.6 28.3
cpv08 20.5 43.3 29.7 54.5 58.7 55.2
cpv09 19.7 46 28.8 81 82 83
cpv10 17.5 43.7 31.9 56.9 64.4 56.6
cpv11 17 45 26.9 77.1 79 78
cpv14 18.3 44.2 30.1 55 56.6 55.1
fdpv1 18.7 53.1 32 34.3 37.4 36
fdpv2 19.1 35.6 37.3 36.2 38.4 36.3
Similarity [E7.tfa]:
bpv1 cpv01 cpv02 cpv03 cpv04 cpv05
bpv1 100 28.3 33.3 23.8 28.2 33.1
cpv01 28.3 100 51.5 64.8 65.7 67
cpv02 33.3 51.5 100 50.5 45.5 51
cpv03 23.8 64.8 50.5 100 88.6 87.6
cpv04 28.2 65.7 45.5 88.6 100 88
cpv05 33.1 67 51 87.6 88 100
cpv06 38.1 78.8 58.7 61.3 63 63.4
cpv07 35.4 53.3 84.7 44.8 42.1 56.6
cpv08 35.6 60.6 49.5 68.2 70.2 73.3
cpv09 34 71 51 89.5 93 91
cpv10 35 62.1 54 71.6 77.9 75.5
cpv11 34 71 50 88.6 91 90
cpv14 33.3 65.4 54 69.4 74.5 69.2
fdpv1 38.1 73.5 56 56.2 59.6 59
fdpv2 36.2 53.8 58.8 57.1 58.6 56.9
cpv06 cpv07 cpv08 cpv09 cpv10 cpv11 cpv14
20.1 16.7 20.5 19.7 17.5 17 18.3
57.6 32.4 43.3 46 43.7 45 44.2
36.5 69.4 29.7 28.8 31.9 26.9 30.1
32.1 25 54.5 81 56.9 77.1 55
37 25.6 58.7 82 64.4 79 56.6
39.6 28.3 55.2 83 56.6 78 55.1
100 30.6 38.5 40.6 38.5 37.6 41
30.6 100 29.8 27 30.5 24.8 29.9
38.5 29.8 100 60 73.1 57.1 80
40.6 27 60 100 61.5 86 58.5
38.5 30.5 73.1 61.5 100 60.6 69.2
37.6 24.8 57.1 86 60.6 100 54.7
41 29.9 80 58.5 69.2 54.7 100
64.9 26.4 36.5 40 37.9 37 37.5
38 37.5 41.3 38.6 43.4 37.6 41.1
cpv06 cpv07 cpv08 cpv09 cpv10 cpv11 cpv14
38.1 35.4 35.6 34 35 34 33.3
78.8 53.3 60.6 71 62.1 71 65.4
58.7 84.7 49.5 51 54 50 54
61.3 44.8 68.2 89.5 71.6 88.6 69.4
63 42.1 70.2 93 77.9 91 74.5
63.4 56.6 73.3 91 75.5 90 69.2
100 53.7 58.7 66.3 62.5 64.4 60
53.7 100 48.2 46.8 49.2 45.1 52.1
58.7 48.2 100 72.4 91.3 75.2 91.4
66.3 46.8 72.4 100 76.9 96 73.6
62.5 49.2 91.3 76.9 100 76.9 88.5
64.4 45.1 75.2 96 76.9 100 74.5
60 52.1 91.4 73.6 88.5 74.5 100
81.4 48.1 59.6 64 59.2 64 61.5
58 55.8 58.7 62.4 57.5 57.4 58.9
fdpv1 fdpv2
18.7 19.1
53.1 35.6
32 37.3
34.3 36.2
37.4 38.4
36 36.3
64.9 38
26.4 37.5
36.5 41.3
40 38.6
37.9 43.4
37 37.6
37.5 41.1
100 35.4
35.4 100
fdpv1 fdpv2
38.1 36.2
73.5 53.8
56 58.8
56.2 57.1
59.6 58.6
59 56.9
81.4 58
48.1 55.8
59.6 58.7
64 62.4
59.2 57.5
64 57.4
61.5 58.9
100 57.6
57.6 100
Identity [L1.tfa]:
bpv1 cpv01 cpv02 cpv03 cpv04 cpv05
bpv1 100 48 47.5 52 50.5 53.1
cpv01 48 100 50.6 53.8 54.7 54
cpv02 47.5 50.6 100 47.3 48.4 50.4
cpv03 52 53.8 47.3 100 71.1 81.7
cpv04 50.5 54.7 48.4 71.1 100 69.6
cpv05 53.1 54 50.4 81.7 69.6 100
cpv06 47 71.3 49.4 52.2 51.8 53.3
cpv07 45.1 50.4 72.4 46.5 47.9 48.6
cpv08 52.2 53.6 51 63.1 63.1 62.9
cpv09 50.5 55.1 49.1 78.1 69.8 79.9
cpv10 53 54.4 51.9 62.3 63.8 61.7
cpv11 51.8 51.8 48.8 76.1 66.5 80.9
cpv14 49.7 53.3 49.8 58 60.6 59.1
fdpv1 45.3 70.8 46.9 49.1 50.4 51.2
fdpv2 50 54.3 52.5 57.9 58.9 60.3
Similarity [L1.tfa]:
bpv1 cpv01 cpv02 cpv03 cpv04 cpv05
bpv1 99.8 72.6 69.8 75.8 74.3 75.9
cpv01 72.6 100 72.9 77.8 76.6 76.2
cpv02 69.8 72.9 100 70.7 73.9 73.3
cpv03 75.8 77.8 70.7 100 86.9 92.4
cpv04 74.3 76.6 73.9 86.9 100 87.3
cpv05 75.9 76.2 73.3 92.4 87.3 100
cpv06 72.2 87.4 72.2 77.6 75.3 77.5
cpv07 70.2 74.8 89.9 71.6 73.4 73.3
cpv08 75.2 76.8 73.2 82.3 82.2 81.9
cpv09 74.9 78.1 70.8 92.6 87.9 92.2
cpv10 77.8 76.5 73.2 82.5 83 81.2
cpv11 77 77.4 73.6 92.2 85.9 92
cpv14 74.6 75.6 71.4 80.1 81.9 79.7
fdpv1 69.6 83 69.2 72.1 71.9 72.5
fdpv2 73.8 77.3 75.3 81.4 79.3 81.8
cpv06 cpv07 cpv08 cpv09 cpv10 cpv11 cpv14
47 45.1 52.2 50.5 53 51.8 49.7
71.3 50.4 53.6 55.1 54.4 51.8 53.3
49.4 72.4 51 49.1 51.9 48.8 49.8
52.2 46.5 63.1 78.1 62.3 76.1 58
51.8 47.9 63.1 69.8 63.8 66.5 60.6
53.3 48.6 62.9 79.9 61.7 80.9 59.1
100 50.3 52.6 52.6 52.4 50.5 53
50.3 100 49.9 49.2 50.6 47.5 49.9
52.6 49.9 100 64.4 74.1 62.5 79.2
52.6 49.2 64.4 100 63 76.7 61.1
52.4 50.6 74.1 63 100 59.2 71.7
50.5 47.5 62.5 76.7 59.2 100 59.3
53 49.9 79.2 61.1 71.7 59.3 100
73.8 47.3 51.9 50.1 50.9 47.8 51.4
55.8 50.3 60.4 60.6 59.3 57.3 59.2
cpv06 cpv07 cpv08 cpv09 cpv10 cpv11 cpv14
72.2 70.2 75.2 74.9 77.8 77 74.6
87.4 74.8 76.8 78.1 76.5 77.4 75.6
72.2 89.9 73.2 70.8 73.2 73.6 71.4
77.6 71.6 82.3 92.6 82.5 92.2 80.1
75.3 73.4 82.2 87.9 83 85.9 81.9
77.5 73.3 81.9 92.2 81.2 92 79.7
100 72.4 76.6 77.2 76.9 76.4 76.2
72.4 100 75.6 74.1 75.5 73.1 73.8
76.6 75.6 100 83 89.9 82.8 93.6
77.2 74.1 83 100 82.6 90.8 81.5
76.9 75.5 89.9 82.6 100 82.2 87.7
76.4 73.1 82.8 90.8 82.2 100 81.8
76.2 73.8 93.6 81.5 87.7 81.8 100
85 69.6 73 72.2 71.7 71.1 72.3
78.4 75.8 80.4 80.7 82.7 79.8 78.7
fdpv1 fdpv2
45.3 50
70.8 54.3
46.9 52.5
49.1 57.9
50.4 58.9
51.2 60.3
73.8 55.8
47.3 50.3
51.9 60.4
50.1 60.6
50.9 59.3
47.8 57.3
51.4 59.2
100 54.4
54.4 100
fdpv1 fdpv2
69.6 73.8
83 77.3
69.2 75.3
72.1 81.4
71.9 79.3
72.5 81.8
85 78.4
69.6 75.8
73 80.4
72.2 80.7
71.7 82.7
71.1 79.8
72.3 78.7
100 73.1
73.1 100
Identity [L2.tfa]:
bpv1 cpv01 cpv02 cpv03 cpv04 cpv05
bpv1 100 27.8 27.6 28.4 28.2 27.8
cpv01 27.8 100 34.3 34.6 35.1 35.3
cpv02 27.6 34.3 100 36 35.7 34.3
cpv03 28.4 34.6 36 100 64.6 77.5
cpv04 28.2 35.1 35.7 64.6 100 65.1
cpv05 27.8 35.3 34.3 77.5 65.1 100
cpv06 26.6 60.5 32.3 33 33.9 35.9
cpv07 27.2 32 62.5 34.4 35.3 34.6
cpv08 27.7 36.3 34 48.8 48.6 49.2
cpv09 26.8 34.4 32.1 67 64.4 72
cpv10 27.8 34.9 35.4 48.1 45.8 49.1
cpv11 24.9 32.8 33.2 69.9 58 72.3
cpv14 27.7 35.9 34.8 48.2 46.8 47.8
fdpv1 27.7 58.7 35 34.4 34.7 36.2
fdpv2 27.6 35.2 30 35.6 35.1 34
Similarity [L2.tfa]:
bpv1 cpv01 cpv02 cpv03 cpv04 cpv05
bpv1 100 51.6 51.5 52.5 48.9 50.5
cpv01 51.6 100 58.4 60.2 58.9 58
cpv02 51.5 58.4 100 58 58.9 55.4
cpv03 52.5 60.2 58 100 81.6 91.1
cpv04 48.9 58.9 58.9 81.6 100 81.1
cpv05 50.5 58 55.4 91.1 81.1 100
cpv06 51.4 82.7 57 58.1 58.7 59.6
cpv07 48.8 55.8 83.6 57.4 57.9 58.2
cpv08 50.7 60 60.8 68.5 68.3 69.8
cpv09 49.7 57.4 54.9 84.4 80.4 86.2
cpv10 47 56.5 58.1 65.5 66.6 68.1
cpv11 47.2 55.5 52.9 84.1 75.2 85.2
cpv14 51.5 58.7 61.6 66.5 67.6 68.2
fdpv1 51.1 80.4 60.7 60.2 59.3 60.9
fdpv2 46.2 57.9 53 53.6 55 53.3
cpv06 cpv07 cpv08 cpv09 cpv10 cpv11 cpv14
26.6 27.2 27.7 26.8 27.8 24.9 27.7
60.5 32 36.3 34.4 34.9 32.8 35.9
32.3 62.5 34 32.1 35.4 33.2 34.8
33 34.4 48.8 67 48.1 69.9 48.2
33.9 35.3 48.6 64.4 45.8 58 46.8
35.9 34.6 49.2 72 49.1 72.3 47.8
100 33.5 35 33.2 34.4 30.4 34.8
33.5 100 34.5 30.1 32.8 30.7 35.5
35 34.5 100 48.6 67.4 48.6 82.4
33.2 30.1 48.6 100 46.4 61.5 47.8
34.4 32.8 67.4 46.4 100 44 67.6
30.4 30.7 48.6 61.5 44 100 47.2
34.8 35.5 82.4 47.8 67.6 47.2 100
68 33.8 37.6 36.8 37.2 32.2 37.1
36.8 33.2 36.5 34.2 36.4 32.3 34.3
cpv06 cpv07 cpv08 cpv09 cpv10 cpv11 cpv14
51.4 48.8 50.7 49.7 47 47.2 51.5
82.7 55.8 60 57.4 56.5 55.5 58.7
57 83.6 60.8 54.9 58.1 52.9 61.6
58.1 57.4 68.5 84.4 65.5 84.1 66.5
58.7 57.9 68.3 80.4 66.6 75.2 67.6
59.6 58.2 69.8 86.2 68.1 85.2 68.2
100 58.7 57 56 59 52.2 59.7
58.7 100 60.2 59.2 56.3 55.1 60.1
57 60.2 100 67.5 82.5 65.9 92.4
56 59.2 67.5 100 67.5 78.3 69.2
59 56.3 82.5 67.5 100 62.8 82.5
52.2 55.1 65.9 78.3 62.8 99.8 64.5
59.7 60.1 92.4 69.2 82.5 64.5 100
86.9 59.3 59.4 60.2 60.1 55.2 59.4
59.2 56 56.7 52.7 56.1 51 57.3
fdpv1 fdpv2
27.7 27.6
58.7 35.2
35 30
34.4 35.6
34.7 35.1
36.2 34
68 36.8
33.8 33.2
37.6 36.5
36.8 34.2
37.2 36.4
32.2 32.3
37.1 34.3
100 36
35.8 100
fdpv1 fdpv2
51.1 46.2
80.4 57.9
60.7 53
60.2 53.6
59.3 55
60.9 53.3
86.9 59.2
59.3 56
59.4 56.7
60.2 52.7
60.1 56.1
55.2 51
59.4 57.3
100 60.1
60.1 100
Supplement 2 
PCR primers for cDNA detection 
Target gene Primer name Sequence 
 
begin end Amplimer length 
Muf_E1_f CCA CCC AAA GTC AGG AGT GT 1807 1826 CPV9 
E1 Muf_E1_r TTA CAT GCT TCG CCT GTG AG 2073 2092 
286 
Muf_E2_f GGG CCA AAG ATG CAA TAG AA 2979 2998 CPV9 
E2 Muf_E2_r TTG GTC AGT CAT GTC CGT GT 3192 3211 
233 
Muf_E4_f TGG AGG GTG ACC TAG AAA CAG 971 991 CPV9 
E4 Muf_E4_r TAC TGA CGC GGT GCA ATC 3983 4000 
3030 (640 on cDNA) 
Muf_E6_f GCG CTC AGG AAT TTC ATT GT 298 317 CPV9 
E6 Muf_E6_r TGA CCA CCT GTT GCG TGT AT 478 497 
200 
Muf_E7_f CAC CAC TTG ACA ACC TCT GG 730 749 CPV9 
E7 Muf_E7_r GGG GCA GCA GAG TGA TGT AT 922 941 
212 
Muf_L1_f TAC TTT CCT GGG GAC AGT GG 6876 6895 CPV9 
L1 Muf_L1_r TTG TTC CAC GTG TGG TGT CT 7058 7077 
202 
Muf_L2_f ATC CTG CGG TAT TTC GTG AG 5142 5161 CPV9 
L2 Muf_L2_r TCC CTG AAC CTT TGA TCT GG 5372 5391 
250 
Hal_E1_f TCA CAG GCC AAA CAC GTA AA 1951 1970 CPV14 
E1 Hal_E1_r CCA AGC AGA CTC ATG CAA AA 2218 2237 
287 
Hal_E2_f ACG CTC AGT GAC ACA AGC AG 2930 2959 CPV14 
E2 Hal_E2_r CCC TTG TGG TCA ACC TGA CT 3124 3123 
194 
Hal_E4_f GGA GGG TGA ACT AGC AGC AG 831 850 CPV14 
E4 Hal_E4_r GTC TGC CTC GAT GTC CTC TC 3970 3989 
3159 (750 on cDNA) 
Hal_E6_f CTC CAA GAA AGA GCG TGA GG 306 325 CPV14 
E6 Hal_E6_r GCC ACC TCC CTC TGA CAT TA 471 490 
185 
Hal_E7_f GGC GCC ACA TTA AGA GAC AT 537 556 CPV14 
E7 Hal_E7_r CAA ATC GAG ACA GGT CAG CA 760 779 
243 
Hal_L1_f GGT GTG ACA GGT CAC CCT CT 6323 6342 CPV14 
L1 Hal_L1_r ACA GTC GCC ACC AGT CTT CT 6513 6532 
210 
Hal_L2_f TTC CCA CAA CAT TTT CGT CA 5048 5067 CPV14 
L2 Hal_L2_r GAA GGC AGG ATC CGT TAC AA 5212 5231 
184 
 
